Tenet Healthcare Corporation vs T-Mobile Us Inc — how do they compare? Tenet Healthcare Corporation trades at $269.36 (market cap $21.67B), while T-Mobile Us Inc trades at $178.67 (market cap $190.23B). The key difference: T-Mobile Us Inc is far larger — about 8.8× Tenet Healthcare Corporation's market cap, and T-Mobile Us Inc pays a 2.3% dividend while Tenet Healthcare Corporation pays none. Which is the better fit depends on your goals.
| THC | TMUS | |
|---|---|---|
Market Cap | $21.67B | $190.23B |
Sector | Health | Media |
52-Week High | $280.77 | $241.67 |
52-Week Low | $161.37 | $167.65 |
Enterprise Value | $32.74B | $306.84B |
Dividend Yield | — | 2.3% |
Signals from Pluang's Aura AI — not financial advice
Tenet Healthcare (THC) trades at $259.06, down 2.26% today, with a bearish technical signal but strong fundamentals. The stock exhibits robust profitability with an 82.83% gross margin and 53.31% ROE, supported by three consecutive quarterly EPS beats. Recent news includes a $2.0 billion senior notes offering for refinancing and participation in the Wells Fargo Healthcare Conference.
Outlook remains positive given analyst consensus of 81.25% buy ratings and a $281.44 price target, implying 8.6% upside. Risks include debt refinancing execution and healthcare regulatory pressures, but earnings momentum and valuation multiples below industry averages present a compelling opportunity for value investors.
T-Mobile US (TMUS) trades at $181.69, showing minimal daily movement with a 0.09% gain. The stock faces bearish technical signals but maintains strong fundamentals with consistent revenue growth from $81.4B in 2024 to $88.3B in 2025 and robust profitability margins. Recent earnings show mixed results with Q1 and Q2 2026 beats but a Q4 2025 miss. The company announced a CFO transition effective February 2027 and continues strategic partnerships, including the Paramount+ Plaza naming rights deal announced September 8, 2026.
TMUS presents a compelling long-term opportunity with 80% analyst buy ratings and a $233.20 consensus price target implying 28% upside. However, rising debt levels (debt-to-asset ratio increased to 39.35% in 2025) and competitive broadband pricing pressures pose risks. The stock's valuation at 19x P/E appears reasonable given sector positioning and growth trajectory, though technical weakness suggests near-term consolidation may continue.
Trailing returns across standard periods
Latest headlines on both assets
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →